Streetwise Articles



Can a Simple Test Really Predict Whether a Cancer Treatment Will Succeed?
Source: Streetwise Reports  (2/20/18)
Imagine if a simple test of a blood or tissue sample could predict whether the standard treatment of care for a cancer would be effective. That day appears to be near for patients with Hodgkin's lymphoma. More >


Analyst's $70 Target Price on Regenerative Medicine Biotech More than a Triple
Source: Streetwise Reports  (2/20/18)
One analyst believes an innovative biotech company that has developed groundbreaking technology to change the way doctors perform body tissue engineering, like skin grafting on burn victims, has the potential to "revolutionize the field of regenerative medicine." More >


Medical Device Firm to Launch Trials for Treatment Targeting $12 Billion Incontinence Market
Source: Streetwise Reports  (2/14/18)
Anthony Vendetti, an analyst with Maxim Group, shared the results both of a pilot study for stress urinary incontinence and of a recent equity raise by this company.
More >


Biotech with Tenbagger Potential Signs Deal with Chinese Firm
Source: Streetwise Reports  (2/14/18)
Joseph Pantginis, an analyst with H. C. Wainwright & Co., detailed prospects for this biopharmaceutical corporation's new partnership with an Asian biotech and other near-term plans.
More >


Company Takes Aim at Approval of Colorectal Cancer Screening Test in EU
Source: Streetwise Reports  (2/13/18)
Two analysts take note as this biotech prepares to release data on its colorectal cancer screening product.
More >


Ron Struthers

The S-Curve Reveals It Is Early Days in the Marijuana Growth Cycle
Source: Ron Struthers for Streetwise Reports  (2/12/18)
Ron Struthers of Struthers Resource Stock Report discusses recent trends in cannabis investing and profiles a handful of cannabis companies. More >


Oncology Biotech with Precision Medicine Focus Added to Analyst's 2018 Top-Pick List
Source: Streetwise Reports  (2/7/18)
A small-cap biotech focused on developing customized treatments for cancer patients has earned inclusion on the NASDAQ Biotechnology Index, as well as caught the eye of analyst Michael King of JMP Securities. More >


Immuno-oncology Pure Play 'Ideally Positioned to Capture Value'
Source: Streetwise Reports  (2/7/18)
Maxim Group analyst Jason McCarthy explained why investors should focus on this emerging technology and one developer that is well-positioned to capture value in the space. More >


Medical Device Firm Boosts Quarterly Revenue 50% YOY
Source: Streetwise Reports  (1/31/18)
A Maxim Group report noted the recently announced revenue achieved and anticipated by this producer of cancer treatment devices. More >


Coverage Initiated on Developer of Potential Breast Cancer Therapy Competitor
Source: Streetwise Reports  (1/31/18)
Jason Kolbert, an analyst with Maxim Group, explained the drivers behind adding this drug and drug delivery developer to his coverage universe. More >


Preliminary Phase 2 Clinical Data Provides 'First Spark to Game-Changing Thesis'
Source: Streetwise Reports  (1/31/18)
H.C. Wainwright & Co. reported on the significance of preliminary data for treatments for head and neck cancer, as well as for cervical cancer. More >


Pancreatic Cancer Trial Data Will Be Released Soon
Source: Streetwise Reports  (1/24/18)
A biotech company that has begun clinical testing of human antibodies to treat cancers is in discussion with potential partners. More >


Coverage Resumed on Developer of 'Drug Candidate with Blockbuster Potential'
Source: Streetwise Reports  (1/24/18)
André Uddin, an analyst with Mackie Research Capital Corp., shared his thesis for investing in this biotech.
More >


Regenerative Medicine Company's China Deal is 'Dramatically Transformational'
Source: Streetwise Reports  (1/18/18)
Echelon Wealth Partners detailed the terms and impact of this cell therapy developer's recent alliance in Asia. More >


Several Milestones on Horizon for 'Top Pick' Immunotherapy Firm
Source: Streetwise Reports  (1/17/18)
Douglas Loe, an analyst with Echelon Partners, outlined the reasons this biotech deserves Top Pick status. More >


Test for Personalized Approach to Hodgkin's Lymphoma Treatment Entering Final Stages Before Commercialization
Source: Streetwise Reports  (1/16/18)
One analyst believes 2018 could mark a 'dramatic turnaround' for this biotech company, which is at the forefront of using three-dimensional telomere analysis to personalize medical treatment. More >


Biotech Offers 'Best-in-Class Potential to Treat Alzheimer's'
Source: Streetwise Reports  (1/10/18)
André Uddin, an analyst with Mackie Research Capital Corp., discussed the implications of the latest announcement about this firm's most advanced Alzheimer's drug. More >


John McCamant

Biotech with Non-Statin Cholesterol Lowering Drug Poised for Significant Catalysts in 2018
Source: John McCamant for Streetwise Reports  (1/10/18)
As 2018 begins, John McCamant, editor of Medical Technology Stock Letter, reviews several 2017 top performers, discusses the turnaround at the FDA, and profiles one company with an innovative non-statin LDL cholesterol in the pipeline. More >


Michael G. King, Jr.

2018 Biotech Watchlist: 'No One Space Is Going to Dominate'
Source: Streetwise Reports  (1/10/18)
Michael King of JMP Securities provides a comprehensive round-up of companies he has selected for the 2018 Biotech Watchlist—companies in immuno-oncology, gene editing, and other indications that he believes offer promising opportunities for patients and investors.
More >


Firm Focused on Women's Health Posts 'Record' Sales of Treatment Device
Source: Streetwise Reports  (1/10/18)
A company marketing a product designed to enhance women's sexual function announced preliminary financial results for Q4/17 that caught the attention of several analysts. More >


Bruce Campbell

Portfolio Manager's Biotech Watchlist Picks for 2018
Source: Streetwise Reports  (1/2/18)
StoneCastle Investment Management has a high-growth fund that invests wherever it finds opportunities, and it is bullish on healthcare. In this interview with The Life Sciences Report, portfolio manager Bruce Campbell highlights four companies that he is putting on Streetwise Reports' 2018 Biotech Watchlist.
More >


When to Take Profits in the Cannabis Sector
Source: Clive Maund for Streetwise Reports  (12/28/17)
With a run-up in cannabis stocks, technical analyst Clive Maund shares his thoughts on when investors should take profits. More >


Biotech's Shares 'Undervalued' and Positioned for 'Long-Term Upside Potential'
Source: Streetwise Reports  (12/27/17)
Zacks Small-Cap Research analyst John Vandermosten reviewed the Q2 FY18 financial results for this epigenetics firm, which is moving forward with a Phase 3 trial targeting heart disease.
More >


Immunotherapy Firm Gets Green Light for Pivotal Trial From FDA
Source: Streetwise Reports  (12/27/17)
Jason Kolbert, an analyst with Maxim Group, described the study, which enables this biotech's device to be used in patients undergoing heart surgery and will measure its effectiveness in reducing a common post-surgical side effect.
More >


'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform
Source: Streetwise Reports  (12/20/17)
Zacks Small-Cap Research's John Vandermosten discussed the potential for this immunotherapy firm's RNAi compounds in oncology. More >


Showing Results: 1 to 25 of 853 Next

Notable Quotes

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe

More Experts